Clinical Efficacy of Adjuvant Chemotherapy in Advanced Upper Tract Urothelial Carcinoma (pT3-T4): Real-World Data from the Taiwan Upper Tract Urothelial Carcinoma Collaboration Group
The clinical efficacy of adjuvant chemotherapy in upper tract urothelial carcinoma (UTUC) is unclear. We aimed to assess the therapeutic outcomes of adjuvant chemotherapy in patients with advanced UTUC (pT3-T4) after radical nephroureterectomy (RNU). We retrospectively reviewed the data of 2108 pati...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Journal of Personalized Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4426/12/2/226 |
| _version_ | 1797478826624679936 |
|---|---|
| author | Chung-Yu Lin Han-Yu Weng Ta-Yao Tai Hsi-Chin Wu Wen-Chi Chen Chung-Hsin Chen Chao-Yuan Huang Chi-Wen Lo Chih-Chin Yu Chung-You Tsai Wei-Che Wu Yuan-Hong Jiang Yu-Khun Lee Thomas Y. Hsueh Allen W. Chiu Bing-Juin Chiang Hsu-Che Huang I-Hsuan Alan Chen Yung-Tai Chen Wei-Yu Lin Chia-Chang Wu Yao-Chou Tsai Hsiang-Ying Lee Wei-Ming Li |
| author_facet | Chung-Yu Lin Han-Yu Weng Ta-Yao Tai Hsi-Chin Wu Wen-Chi Chen Chung-Hsin Chen Chao-Yuan Huang Chi-Wen Lo Chih-Chin Yu Chung-You Tsai Wei-Che Wu Yuan-Hong Jiang Yu-Khun Lee Thomas Y. Hsueh Allen W. Chiu Bing-Juin Chiang Hsu-Che Huang I-Hsuan Alan Chen Yung-Tai Chen Wei-Yu Lin Chia-Chang Wu Yao-Chou Tsai Hsiang-Ying Lee Wei-Ming Li |
| author_sort | Chung-Yu Lin |
| collection | DOAJ |
| description | The clinical efficacy of adjuvant chemotherapy in upper tract urothelial carcinoma (UTUC) is unclear. We aimed to assess the therapeutic outcomes of adjuvant chemotherapy in patients with advanced UTUC (pT3-T4) after radical nephroureterectomy (RNU). We retrospectively reviewed the data of 2108 patients from the Taiwan UTUC Collaboration Group between 1988 and 2018. Comprehensive clinical features, pathological characteristics, and survival outcomes were recorded. Univariate and multivariate Cox proportional hazards models were used to evaluate overall survival (OS), cancer-specific survival (CSS), and disease-free survival (DFS). Of the 533 patients with advanced UTUC included, 161 (30.2%) received adjuvant chemotherapy. In the multivariate analysis, adjuvant chemotherapy was significantly associated with a reduced risk of overall death (hazard ratio (HR), 0.599; 95% confidence interval (CI), 0.419–0.857; <i>p</i> = 0.005), cancer-specific mortality (HR, 0.598; 95% CI, 0.391–0.914; <i>p</i> = 0.018), and cancer recurrence (HR, 0.456; 95% CI, 0.310–0.673; <i>p</i> < 0.001). The Kaplan–Meier survival analysis revealed that patients receiving adjuvant chemotherapy had significantly better five-year OS (64% vs. 50%, <i>p</i> = 0.002), CSS (70% vs. 62%, <i>p</i> = 0.043), and DFS (60% vs. 48%, <i>p</i> = 0.002) rates compared to those who did not receive adjuvant chemotherapy. In conclusion, adjuvant chemotherapy after RNU had significant therapeutic benefits on OS, CSS, and DFS in advanced UTUC. |
| first_indexed | 2024-03-09T21:37:07Z |
| format | Article |
| id | doaj.art-3c3016cb74de45279df5a682700a1227 |
| institution | Directory Open Access Journal |
| issn | 2075-4426 |
| language | English |
| last_indexed | 2024-03-09T21:37:07Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Personalized Medicine |
| spelling | doaj.art-3c3016cb74de45279df5a682700a12272023-11-23T20:40:10ZengMDPI AGJournal of Personalized Medicine2075-44262022-02-0112222610.3390/jpm12020226Clinical Efficacy of Adjuvant Chemotherapy in Advanced Upper Tract Urothelial Carcinoma (pT3-T4): Real-World Data from the Taiwan Upper Tract Urothelial Carcinoma Collaboration GroupChung-Yu Lin0Han-Yu Weng1Ta-Yao Tai2Hsi-Chin Wu3Wen-Chi Chen4Chung-Hsin Chen5Chao-Yuan Huang6Chi-Wen Lo7Chih-Chin Yu8Chung-You Tsai9Wei-Che Wu10Yuan-Hong Jiang11Yu-Khun Lee12Thomas Y. Hsueh13Allen W. Chiu14Bing-Juin Chiang15Hsu-Che Huang16I-Hsuan Alan Chen17Yung-Tai Chen18Wei-Yu Lin19Chia-Chang Wu20Yao-Chou Tsai21Hsiang-Ying Lee22Wei-Ming Li23Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung 807, TaiwanDepartment of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, TaiwanDepartment of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, TaiwanDepartment of Urology, China Medical University Hospital, Taichung 404, TaiwanDepartment of Urology, China Medical University Hospital, Taichung 404, TaiwanDepartment of Urology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei 100, TaiwanDepartment of Urology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei 100, TaiwanDivision of Urology, Department of Surgery, Taipei Tzu Chi Hospital, The Buddhist Medical Foundation, New Taipei City 231, TaiwanDivision of Urology, Department of Surgery, Taipei Tzu Chi Hospital, The Buddhist Medical Foundation, New Taipei City 231, TaiwanDivision of Urology, Department of Surgery, Far Eastern Memorial Hospital, New Taipei City 220, TaiwanDivision of Urology, Department of Surgery, Far Eastern Memorial Hospital, New Taipei City 220, TaiwanDepartment of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien 970, TaiwanDepartment of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien 970, TaiwanDivision of Urology, Department of Surgery, Taipei City Hospital Renai Branch, Taipei 106, TaiwanCollege of Medicine, National Yang Ming Chiao Tung University, Taipei 112, TaiwanCollege of Medicine, Fu-Jen Catholic University, New Taipei City 242, TaiwanDivision of Urology, Department of Surgery, Cardinal Tien Hospital, New Taipei City 231, TaiwanDivision of Urology, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung 813, TaiwanDepartment of Urology, Taiwan Adventist Hospital, Taipei 105, TaiwanDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital, Chia-Yi 613, TaiwanDepartment of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City 235, TaiwanDepartment of Urology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, TaiwanDepartment of Urology, Kaohsiung Medical University Hospital, Kaohsiung 807, TaiwanDepartment of Urology, Kaohsiung Medical University Hospital, Kaohsiung 807, TaiwanThe clinical efficacy of adjuvant chemotherapy in upper tract urothelial carcinoma (UTUC) is unclear. We aimed to assess the therapeutic outcomes of adjuvant chemotherapy in patients with advanced UTUC (pT3-T4) after radical nephroureterectomy (RNU). We retrospectively reviewed the data of 2108 patients from the Taiwan UTUC Collaboration Group between 1988 and 2018. Comprehensive clinical features, pathological characteristics, and survival outcomes were recorded. Univariate and multivariate Cox proportional hazards models were used to evaluate overall survival (OS), cancer-specific survival (CSS), and disease-free survival (DFS). Of the 533 patients with advanced UTUC included, 161 (30.2%) received adjuvant chemotherapy. In the multivariate analysis, adjuvant chemotherapy was significantly associated with a reduced risk of overall death (hazard ratio (HR), 0.599; 95% confidence interval (CI), 0.419–0.857; <i>p</i> = 0.005), cancer-specific mortality (HR, 0.598; 95% CI, 0.391–0.914; <i>p</i> = 0.018), and cancer recurrence (HR, 0.456; 95% CI, 0.310–0.673; <i>p</i> < 0.001). The Kaplan–Meier survival analysis revealed that patients receiving adjuvant chemotherapy had significantly better five-year OS (64% vs. 50%, <i>p</i> = 0.002), CSS (70% vs. 62%, <i>p</i> = 0.043), and DFS (60% vs. 48%, <i>p</i> = 0.002) rates compared to those who did not receive adjuvant chemotherapy. In conclusion, adjuvant chemotherapy after RNU had significant therapeutic benefits on OS, CSS, and DFS in advanced UTUC.https://www.mdpi.com/2075-4426/12/2/226upper tract urothelial carcinomachemotherapyprognosis |
| spellingShingle | Chung-Yu Lin Han-Yu Weng Ta-Yao Tai Hsi-Chin Wu Wen-Chi Chen Chung-Hsin Chen Chao-Yuan Huang Chi-Wen Lo Chih-Chin Yu Chung-You Tsai Wei-Che Wu Yuan-Hong Jiang Yu-Khun Lee Thomas Y. Hsueh Allen W. Chiu Bing-Juin Chiang Hsu-Che Huang I-Hsuan Alan Chen Yung-Tai Chen Wei-Yu Lin Chia-Chang Wu Yao-Chou Tsai Hsiang-Ying Lee Wei-Ming Li Clinical Efficacy of Adjuvant Chemotherapy in Advanced Upper Tract Urothelial Carcinoma (pT3-T4): Real-World Data from the Taiwan Upper Tract Urothelial Carcinoma Collaboration Group Journal of Personalized Medicine upper tract urothelial carcinoma chemotherapy prognosis |
| title | Clinical Efficacy of Adjuvant Chemotherapy in Advanced Upper Tract Urothelial Carcinoma (pT3-T4): Real-World Data from the Taiwan Upper Tract Urothelial Carcinoma Collaboration Group |
| title_full | Clinical Efficacy of Adjuvant Chemotherapy in Advanced Upper Tract Urothelial Carcinoma (pT3-T4): Real-World Data from the Taiwan Upper Tract Urothelial Carcinoma Collaboration Group |
| title_fullStr | Clinical Efficacy of Adjuvant Chemotherapy in Advanced Upper Tract Urothelial Carcinoma (pT3-T4): Real-World Data from the Taiwan Upper Tract Urothelial Carcinoma Collaboration Group |
| title_full_unstemmed | Clinical Efficacy of Adjuvant Chemotherapy in Advanced Upper Tract Urothelial Carcinoma (pT3-T4): Real-World Data from the Taiwan Upper Tract Urothelial Carcinoma Collaboration Group |
| title_short | Clinical Efficacy of Adjuvant Chemotherapy in Advanced Upper Tract Urothelial Carcinoma (pT3-T4): Real-World Data from the Taiwan Upper Tract Urothelial Carcinoma Collaboration Group |
| title_sort | clinical efficacy of adjuvant chemotherapy in advanced upper tract urothelial carcinoma pt3 t4 real world data from the taiwan upper tract urothelial carcinoma collaboration group |
| topic | upper tract urothelial carcinoma chemotherapy prognosis |
| url | https://www.mdpi.com/2075-4426/12/2/226 |
| work_keys_str_mv | AT chungyulin clinicalefficacyofadjuvantchemotherapyinadvanceduppertracturothelialcarcinomapt3t4realworlddatafromthetaiwanuppertracturothelialcarcinomacollaborationgroup AT hanyuweng clinicalefficacyofadjuvantchemotherapyinadvanceduppertracturothelialcarcinomapt3t4realworlddatafromthetaiwanuppertracturothelialcarcinomacollaborationgroup AT tayaotai clinicalefficacyofadjuvantchemotherapyinadvanceduppertracturothelialcarcinomapt3t4realworlddatafromthetaiwanuppertracturothelialcarcinomacollaborationgroup AT hsichinwu clinicalefficacyofadjuvantchemotherapyinadvanceduppertracturothelialcarcinomapt3t4realworlddatafromthetaiwanuppertracturothelialcarcinomacollaborationgroup AT wenchichen clinicalefficacyofadjuvantchemotherapyinadvanceduppertracturothelialcarcinomapt3t4realworlddatafromthetaiwanuppertracturothelialcarcinomacollaborationgroup AT chunghsinchen clinicalefficacyofadjuvantchemotherapyinadvanceduppertracturothelialcarcinomapt3t4realworlddatafromthetaiwanuppertracturothelialcarcinomacollaborationgroup AT chaoyuanhuang clinicalefficacyofadjuvantchemotherapyinadvanceduppertracturothelialcarcinomapt3t4realworlddatafromthetaiwanuppertracturothelialcarcinomacollaborationgroup AT chiwenlo clinicalefficacyofadjuvantchemotherapyinadvanceduppertracturothelialcarcinomapt3t4realworlddatafromthetaiwanuppertracturothelialcarcinomacollaborationgroup AT chihchinyu clinicalefficacyofadjuvantchemotherapyinadvanceduppertracturothelialcarcinomapt3t4realworlddatafromthetaiwanuppertracturothelialcarcinomacollaborationgroup AT chungyoutsai clinicalefficacyofadjuvantchemotherapyinadvanceduppertracturothelialcarcinomapt3t4realworlddatafromthetaiwanuppertracturothelialcarcinomacollaborationgroup AT weichewu clinicalefficacyofadjuvantchemotherapyinadvanceduppertracturothelialcarcinomapt3t4realworlddatafromthetaiwanuppertracturothelialcarcinomacollaborationgroup AT yuanhongjiang clinicalefficacyofadjuvantchemotherapyinadvanceduppertracturothelialcarcinomapt3t4realworlddatafromthetaiwanuppertracturothelialcarcinomacollaborationgroup AT yukhunlee clinicalefficacyofadjuvantchemotherapyinadvanceduppertracturothelialcarcinomapt3t4realworlddatafromthetaiwanuppertracturothelialcarcinomacollaborationgroup AT thomasyhsueh clinicalefficacyofadjuvantchemotherapyinadvanceduppertracturothelialcarcinomapt3t4realworlddatafromthetaiwanuppertracturothelialcarcinomacollaborationgroup AT allenwchiu clinicalefficacyofadjuvantchemotherapyinadvanceduppertracturothelialcarcinomapt3t4realworlddatafromthetaiwanuppertracturothelialcarcinomacollaborationgroup AT bingjuinchiang clinicalefficacyofadjuvantchemotherapyinadvanceduppertracturothelialcarcinomapt3t4realworlddatafromthetaiwanuppertracturothelialcarcinomacollaborationgroup AT hsuchehuang clinicalefficacyofadjuvantchemotherapyinadvanceduppertracturothelialcarcinomapt3t4realworlddatafromthetaiwanuppertracturothelialcarcinomacollaborationgroup AT ihsuanalanchen clinicalefficacyofadjuvantchemotherapyinadvanceduppertracturothelialcarcinomapt3t4realworlddatafromthetaiwanuppertracturothelialcarcinomacollaborationgroup AT yungtaichen clinicalefficacyofadjuvantchemotherapyinadvanceduppertracturothelialcarcinomapt3t4realworlddatafromthetaiwanuppertracturothelialcarcinomacollaborationgroup AT weiyulin clinicalefficacyofadjuvantchemotherapyinadvanceduppertracturothelialcarcinomapt3t4realworlddatafromthetaiwanuppertracturothelialcarcinomacollaborationgroup AT chiachangwu clinicalefficacyofadjuvantchemotherapyinadvanceduppertracturothelialcarcinomapt3t4realworlddatafromthetaiwanuppertracturothelialcarcinomacollaborationgroup AT yaochoutsai clinicalefficacyofadjuvantchemotherapyinadvanceduppertracturothelialcarcinomapt3t4realworlddatafromthetaiwanuppertracturothelialcarcinomacollaborationgroup AT hsiangyinglee clinicalefficacyofadjuvantchemotherapyinadvanceduppertracturothelialcarcinomapt3t4realworlddatafromthetaiwanuppertracturothelialcarcinomacollaborationgroup AT weimingli clinicalefficacyofadjuvantchemotherapyinadvanceduppertracturothelialcarcinomapt3t4realworlddatafromthetaiwanuppertracturothelialcarcinomacollaborationgroup |